Breast Cancer

Two denosumab biosimilars have been approved by the FDA for all previously approved uses for the reference drugs in cancers and osteoporosis.

Jessie Desir, PhD, RN, AMB-BC, OCN, discussed the need for awareness about cancer subtypes and their prevalence in certain populations.

Although participants in the study had greater rates of nonadherence postintervention, those who reported nonadherence at baseline saw some increase in adherence.

Camizestrant with a CDK4/6 inhibitor was well tolerated and effective as first-line therapy for patients with ESR1-mutated, HR-positive/HER2-negative advanced breast cancer.

Erica S. Doubleday, MS, FNP-C, BSN, RN, discussed taking advantage of available resources to provide comprehensive care for patients with breast cancer.

T-DM1 reduced risk of invasive disease events and death compared with trastuzumab in HER2-positive early breast cancer with residual invasive disease after neoadjuvant therapy.

The role of oncology nurses and APPs in research is largely to stay abreast of trials that may be useful to patients and recommend them whenever possible, according to Erica Doubleday, MS, FNP-C, BSN, RN.

Patients with recurrent/metastatic HER2-positive breast cancer experienced durable response and manageable safety from KN026-docetaxel combination therapy.

Lerociclib plus fulvestrant demonstrated a progression-free survival (PFS) advantage across all patient subgroups with HR–positive, HER2–negative advanced breast cancer.

Erica S. Doubleday, MS, FNP-C, BSN, RN, illustrated the importance of consistent care to identify AEs like interstitial lung disease in patients with cancer.

After a phase 3 study showed a promising pCR rate with HLX11, the pertuzumab biosimilar’s BLA has been accepted for review by the FDA.

The FDA has approved a companion diagnostic to determine if patients with HR-positive, HER2-ultralow metastatic breast cancer are eligible for T-DXd treatment.

Erica S. Doubleday, MS, FNP-C, BSN, RN, explains AEs commonly associated with use of trastuzumab deruxtecan.

Inavolisib in combination with palbociclib and fulvestrant improved overall survival compared to palbociclib and fulvestrant alone in patients with PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer.

Erica S. Doubleday, MS, FNP-C, BSN, RN, outlined upcoming approvals and care options for providers to expect in the breast cancer space.

La-Urshalar Brock, FNP-BC, CNM, RNFA, spoke about the oncology nurse’s and APP’s roles in managing chemotherapy-induced peripheral neuropathy in patients with breast cancer.

An APP’s research is focused on chemo-induced peripheral neuropathy in Black breast cancer survivors and its impact on their long-term quality of life.

An oncology nurse practitioner's transition from private practice to cancer research offers insights for nurses exploring new career paths within oncology.

Oncology nurses can educate patients about the potential indications for oncolytic virus therapy and connect them to available clinical trial opportunities.

Oncology nurses can educate patients on the implications of these findings

Ribociclib plus endocrine therapy shows PFS benefit in luminal B/HER2E breast cancer subtypes compared to chemotherapy, especially with low immune-related gene expression.

Additional exploration may help fully realize the impact of combining immunologic approaches with PARP inhibition, says one expert.

Baseline ctDNA presence was associated with larger tumor size and higher residual disease burden scores following neoadjuvant endocrine therapy in HR-positive, early breast cancer.

Perioperative atezolizumab did not improve outcomes in patients with triple-negative breast cancer.

A phase 1 trial of camizestrant with ribociclib appears safe and effective in patients with ER+/HER2- advanced breast cancer.